EANO - EORTC Educational Day

Wednesday, October 12
Room: Musensaal

19:30 – 21:30 **Special Lecture & Get together**  
*Chair:* Wolfgang Wick, Heidelberg/DE  
The role of infections in neurodegenerative diseases and some common cancers;  
*Harald zur Hausen, Heidelberg/DE*

Thursday, October 13
Room: Arnold Schönberg

08:45 – 09:00 **Welcome**  
*Wolfgang Wick, Heidelberg/DE (EANO)*  
*Martin van den Bent, Rotterdam/NL (EORTC)*

09:00 – 10:45 **Disease Overview**  
*Chairs:* Christine Marosi, Vienna/AT; Martin van den Bent, Rotterdam/NL  
Clinical concepts glioma; *Colin Watts, Cambridge/UK*  
Clinical concepts meningioma; *Roger Henriksson, Umea/SE*  
Preclinical concepts glioma; *Joan Seoane, Barcelona/ES*  
Preclinical concepts meningioma; *Christian Mawrin, Magdeburg/DE*

10:45 – 11:15 **Coffee Break**

11:15 – 12:30 **Molecular & Pathological Diagnosis**  
*Chairs:* Geoff Pilkington, Portsmouth/UK  
Neuropathology of glioma; *Guido Reifenberger, Düsseldorf/DE*  
Molecular Neuropathology of Meningioma; *Felix Sahm, Heidelberg/DE*  
Clinically relevant molecular diagnostics in glioma; *Ahmed Idbaih, Paris/FR*  
Clinically relevant molecular diagnostics in meningioma; *Matthias Preusser, Vienna/AT*

12:30 – 13:15 **Lunch Break**

13:15 – 14:15 **Advanced Technology**  
*Chairs:* Roger Henriksson, Umea/SE; Michael Platten, Heidelberg/DE  
Clinical applications of amino acid PET in Neuro-Oncology; *Norbert Galldiks, Cologne/DE*  
Imaging challenges in meningioma; *Martha Nowosielski, Innsbruck/AT*  
Liquid biopsy; *Klaus Pantel, Hamburg/DE*

14:15 – 15:30 **Last Two Years in Trials & Guideline Development**  
*Chairs:* Clemens Dirven, Rotterdam/NL; Uwe Schlegel, Bochum/DE  
Glioma; *Wolfgang Wick, Heidelberg/DE*  
Meningioma; *Ricardo Soffietti, Torino/IT*  
Glioma guidelines; *Michael Weller, Zurich/CH*  
Meningioma guidelines; *Roland Goldbrunner, Cologne/DE*
15:30 – 16:00  Coffee Break

16:00 – 17:30  Bioinformatics in Neuro-Oncology
   Chairs: Guido Reifenberger, Düsseldorf/DE; Michael Weller, Zurich/CH
   How to interpret big data; Monika Hegi, Lausanne/CH
   Pitfalls in trial conduct and interpretation; Martin van den Bent, Rotterdam/NL
   Modelling; Benedikt Brors, Heidelberg/DE
Educational Day for Nurses

Thursday, October 13

Room: Johann Wenzel Stammitz

Chairs: Ingela Oberg, Cambridge/UK

09:00 – 09:20  Welcome & Introductions
  Ingela Oberg Cambridge/UK

09:20 – 10:30  3-D Neuro Anatomy
  Thomas Santarius, Cambridge/UK

10:30 – 11:00  Coffee Break

Chairs: Ingela Oberg, Cambridge/UK; Karin Piil, Copenhagen/DK

11:00 – 11:30  Surgery and Insular LGG’s – Advancing Techniques
  Lorenzo Bello, Milan/IT

11:30 – 12:00  Molecular Markers in LGG’s and their impact on patient management
  Andreas von Deimling, Heidelberg/DE

12:00 – 12:30  Oncological Advances for LGG’s
  Catherine McBain, Manchester/UK

12:30 – 13:30  Lunch Break

Chairs: Ingela Oberg, Cambridge/UK; Helen Bulbeck, Cambridge/UK

13:30 – 14:00  Epilepsy Management of LGG’s
  Robin Grant, Edinburgh/UK

14:00 – 14:30  Managing challenging behaviour for the LGG Patient
  Wolfgang Wick, Heidelberg/DE

14:30 – 15:00  Neuro-Rehabilitation for Brain Tumour Patients
  Michelangelo Bartolo, Pozzilli/IT

15:00 – 15:30  Coffee Break

Chairs: Ingela Oberg, Cambridge/UK; Hanneke Zwinkels, The Hague/NL

15:30 – 16:00  Neuropsychology Input
  Martin Klein, Amsterdam/NL

16:00 – 17:00  Closing Remarks & Discussion
  Ingela Oberg, Cambridge/UK
Nurse Session

Friday, October 14

Room: Johann Wenzel Stammitz

**Chairs:** Ingela Oberg, Cambridge/UK; Kate Burton, Cambridge/UK

08:50 – 09:00  Welcome & Introductions
               *Ingela Oberg* Cambridge/UK

09:00 – 09:30  Person-centred care in the Netherlands
               *Claudia van Opstal; Sandra Bossmann, Nijmegen/NL*

09:30 – 10:00  Involving young care givers and family
               *Delmy Olivia; Lena Rosenlund; Asa Ahlstrom, Jonkoping/SE*

10:00 – 10:30  Patient involvement in research priorities (PIRE)
               *Karin Piil, Copenhagen/DK*

10:30 – 11:00  Coffee Break

**Chairs:** Ingela Oberg, Cambridge/UK; Karin Piil, Copenhagen/DK

11:00 – 12:30  Writing for publication workshop
               *Stewart Piper, Cambridge/UK*

12:30 – 13:00  Collaborative Educational Needs and Goals
               *Hanneke Zwinkels, Leidschendam/NL*

13:00 – 14:00  Lunch Break

**Chairs:** Ingela Oberg, Cambridge/UK; Helen Bulbeck, Cambridge/UK; Hanneke Zwinkels, The Hague/NL

14:00 – 14:30  Role of a Consultant AHP Radiographer
               *Kate Burton, Cambridge/UK*

14:30 – 16:00  Interpreting the evidence workshop
               *Lucinda Billingham, Birmingham/UK*

16:00 – 16:45  Feedback/Closing discussions
               *Ingela Oberg Cambridge/UK*
08:00 – 09:00  Sunrise Session - Molecular Diagnostics / Practise Session
Room: Alban Berg
Chairs: Johan M. Kros, Rotterdam/NL; Ghazaleh Tabatabai, Tuebingen/DE
Biomarker assessment I (single markers); Aden Chan, Hongkong/HK
Biomarker assessment II (panels/chips); Andreas von Deimling, Heidelberg/DE
Biomarkers for daily clinical use; Patrick Roth, Zurich/CH
Biomarkers for clinical trials; Pim French, Rotterdam/NL

09:00 – 10:30  Meet the Expert Session – Patient-Centered Outcomes
Room: Gustav Mahler
Chairs: Robin Grant, Edinburgh/UK; Roberta Ruda, Torino/IT
Cognitive testing: impact of medical therapies; Jeffrey Wefel, Houston/US
Cognitive functioning: role of surgery; Esther Habets, The Hague/NL
Longitudinal measures for HRQoL; Martin Taphoorn, The Hague/NL
PCO: Implementation into clinical trials, Roger Henriksson, Umeå/SE

Meet the Expert Session - Scales and Imaging
Room: Arnold Schönberg
Chairs: Ulrich Herrlinger, Bonn/DE; Tracy Todd Batchelor, Boston/US
Uniform imaging master protocol; Martin Bendszus, Heidelberg/DE
iRANO; Michael Weller, Zurich/CH
NANO; David Reardon, Boston/US
Mets RANO; Brigitta Baumert, Bonn/DE

Meet the Expert Session - Radiotherapy innovations aimed at minimising neurotoxicity
Room: Alban Berg
Chairs: Elizabeth Cohen-Jonathan Moyal, Toulouse/FR; Jürgen Debus, Heidelberg/DE
Photons - including VMAT and hippocampal sparin; Frank Lagerwaard, Amsterdam/NL
Protons; Damien Charles Weber, Geneva/CH
Optimising target definition by incorporating functional imaging,
Karim-Maximilian Niyazi, Munich/DE
Experimental outlook; Amir Abdollahi, Heidelberg/DE

10:30 – 11:00  Coffee Break

11:00-13:00  Oral Session - Cell Biology
Room: Gustav Mahler
Chairs: Florence Lefranc, Lille/FR; Simone Niclou, Luxembourg/LU
Actin cytoskeleton regulator ARP2/3 complex is required for DLL1 activating NOTCH1 signaling to maintain the stem cell phenotype of brain tumor stem cells; Chen Zhang, Tianjin/CN
Effects of the IDH1R132H mutation on redox-status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation; Barbara Klink, Dresden/DE

Myc downstream regulated gene 1 (NDRG1) influences the glioma tumor microenvironment; Carina Thomé, Heidelberg/DE

Current treatment regimens induce the mTORC1 inhibitor REDD1 in human glioblastoma cells: implications for treatment efficacy; Michael Ronellenfitsch, Frankfurt/DE

Fluvoxamine (SSRI), inhibits glioblastoma invasion by inhibition of actin polymerization; Hiroyuki Michiue, Okayama City/JP

Tumor Microtubes contribute to resistance against surgical lesions, and chemotherapy in malignant glioma; Sophie Weil, Heidelberg/DE

Regulatory RNAs, a missing link in Glioblastoma response to Temozolomide?; Sabrina Fritah, Luxembourg/LU

IRE1-mediated immunomodulation in glioblastoma; Tony Avril, Rennes/FR

TMIC-02. targeting carcinoma-astrocyte gap junctions in brain metastasis; Adrienne Boire, New York/US

Oral Session – Immunology

Room: Arnold Schönberg

Chairs: Michael Platten, Heidelberg/DE; Patrick Roth, Zurich/CH

Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas; Theresa Bunse, Heidelberg/DE

Paracrine impairment of antitumor T cell immunity by IDH1-mutant gliomas; Lukas Bunse, Heidelberg/DE

A mutation-specific vaccination approach for Histon H3.3 K27M-mutated gliomas; Katharina Ochs, Heidelberg/DE

Expression and relevance of tumoral and stromal MHC class II in gliomas; Felix Sahm, Heidelberg/DE

Long term remission/survival over 8 years in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 dendritic cell-based immunotherapy (phase I); Surasak Phuphanich, Los Angeles/US

Identification of IDH1R132H-specific T cell receptors from a humanized mouse model and from glioma patients treated with an IDH1R132H-specific peptide vaccine; Khwab Sanghvi, Heidelberg/DE

An open-labelled, randomized phase II study in patients with recurrent Glioblastoma Multiforme comparing progression free survival of ALECSAT (Autologous lymphoid effector cells specific against tumour-cells) versus Bevacizumab/Irinotecan; Charlotte Haslund, Aalborg/DK

Survival gain and immune response in glioblastoma patients treated with dendritic cell immunotherapy before and during adjuvant temozolomide; Marica Eoli, Milan/IT
Oral Session – Models
Room: Alban Berg

Chairs: Colin Watts, Cambridge/UK; David Jones, Heidelberg/DE

Differential impact of Ang-2, VEGF-A and dual Ang-2/VEGF-A blocking on the efficacy of radio- and chemotherapy in a glioblastoma model; Gergely Solecki, Heidelberg/DE

Delta-aminolevulinic acid can decrease the radioresistance of glioma stem cells with mesenchymal phenotypes in vitro and in vivo; Yangtae Park, Takatsuki/JP

Role of pericytes in angiogenesis-dependent growth of malignant glioma; Yoshihiro Otani, Okayama/JP

Effect of bevacizumab on the morphology and function of neurons and glial cells; Pauline Latzer, Bochum/DE

Gene expression landscape including miRNAs of delayed radiation necrosis in brain; Naosuke Nonoguchi, Takatsuki/JP

Optical Biopsies in Neurosurgery: Raman Spectroscopy for the Real-time Identification of Tumours during Surgery; Babar Vaqas, London/UK

Tyrosine phosphorylation of nuclear PTEN promotes therapeutic resistance through enhanced DNA damage repair; Frank Furnari, San Diego/US

Understanding medulloblastoma dispersal using an all human in vitro model; Helen Fillmore, Portsmouth/UK

13:15 – 14:15 Lunch Break / Industry Sponsored Symposium

14:30-14:45 Opening and Presidential Address

14:45-15:30 Keynote Lecture EANO
Room: Gustav Mahler

Chairs: Ricardo Soffietti, Torino/IT

Clinical trials in anaplastic gliomas; Martin van den Bent, Rotterdam/NL

15:30 – 17:00 Plenary Session – Neuro-Oncology at the limits: Stem cells and heterogeneity
Room: Gustav Mahler

Chairs: Monika Hegi, Lausanne/CH; Sevin Turcan, Heidelberg/DE

Transgenic animal models; Haikun Liu, Heidelberg/DE

Cancer stem cells in glioma: an evolving concept; Simone Niclou, Luxembourg/LU

Stem cell-directed neurosurgery; Colin Watts, Cambridge/UK

Plenary Session - Brain Metastases
Room: Arnold Schönberg

Chairs: Clemens Dirven, Rotterdam/NL; Christine Marosi, Vienna/AT

Modelling/new targets; Frits Thorsen, Bergen/NO

Genetics and heterogeneity; Priscilla Brastianos, Boston/US

Recent concepts in surgery; Philippe Metellus, Marseille/FR

Recent concepts in radiotherapy; Elizabeth Cohen-Jonathan Moyal, Toulouse/FR

Recent concepts in medical treatment; Riccardo Soffietti, Torino/IT
Plenary Session - Pediatric Neuro-Oncology - rapid (pre-) clinical developments

Room: Alban Berg

Chairs: Guido Reifenberger, Düsseldorf/DE; David Jones, Heidelberg/DE

Epigenetic landscape non-glioma in children; Stefan Pfister, Heidelberg/DE
Ependymoma in children; Didier Frappaz, Lyon/FR
Genome and transcriptome analysis in HGG; Nada Jabado, Montreal/CA
Molecular targeted therapy concepts; David Jones, Heidelberg/DE

17:00–18:00  Poster viewing

18:00 - 19:30  Industry Sponsored Symposium
Room: Gustav Mahler
Saturday, October 15

07:00-08:00  **Sunrise Session - EANM Session - PET imaging**  
**Room:** Arnold Schönberg  
**Chairs:** Ian Law, Copenhagen/DK; Jörg Tonn, Munich/DE  
Glioma WHO II - when do I need a PET scan; Christian La Fougere, Tübingen/DE  
AA-PET for differential diagnosis of tumor progression in malignant glioma; Norbert Galldiks, Cologne/DE  
PET/MRI in neurooncology; Ian Law, Copenhagen/DK

08:00-09:00  **Meet the Expert Session - Immuno(neuro)oncology**  
**Room:** Gustav Mahler  
**Chairs:** David Reardon, Boston/US; Andreas von Deimling, Heidelberg/DE  
Are there biomarkers?; Matthias Preusser, Vienna/AT  
Active vaccination and beyond; Michael Weller, Zurich/CH  
Checkpoint inhibition: quo vadis in glioma?; David Reardon, Boston/US  
New concepts; Michael Platten, Heidelberg/DE

**Meet the Expert Session - Impact of Metabolism on Brain Tumor Treatment**  
**Room:** Arnold Schönberg  
**Chairs:** Ufuk Abacouglu, Istanbul/TR; Joachim Steinbach, Frankfurt/DE  
Targeting Glucose Metabolism in Brain Tumor Therapy: Concepts and Applications; Joachim Steinbach, Frankfurt/DE  
Tryptophan metabolism: key to glioma immunotherapy; Christiane Opitz, Heidelberg/DE  
Novel insights into the metabolic aberrations in IDH mutant glioma; Simone Niclou, Luxembourg/LU

**Meet the Expert Session - Challenges of Neuro-Oncology in Adolescents/Young Adults**  
**Room:** Alban Berg  
**Chairs:** Peter Hau, Regensburg/DE; Andreas Hottinger, Lausanne/CH  
Biological specifics; Ho Ng; Hongkong/HK  
Young primary diagnosis older relapse; Olaf Witt, Heidelberg/DE  
Do we need age specific trials for TYAs; Frank Saran, London/UK

09:00-10:00  **Special Session - Update on Glioma Trials**  
**Room:** Gustav Mahler  
**Chairs:** Elizabeth Cohen-Jonathan Moyal, Toulouse/FR; Roberta Ruda, Torino/IT  
Angiogenesis; Oliver Chinot, Marseille/FR  
Viral Trials; Zvi Ram, Tel Aviv/IS  
Immunotherapy; Wolfgang Wick, Heidelberg/DE  
Electric fields; Andreas Hottinger, Lausanne/CH
10:00-10:30  **EANO Highlights**  
Room: Gustav Mahler  
**Chairs:** Michael Weller, Zurich/CH

Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion, an intergroup trial; *Martin van den Bent, Rotterdam/NL*

Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ; *Natividad Gomez-Roman, Glasgow/UK*

EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma; *Martin van den Bent, Rotterdam/NL*


10:30 – 11:00  **Coffee Break**

11:00-13:00  **Oral Session - Biomarker**  
Room: Gustav Mahler  
**Chairs:** Geoff Pilkington, Portsmouth/UK; Guido Reifenberger, Düsseldorf/DE

Detection of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for diagnosing IDH1 mutant glioma; *Kazuhiro Tanaka, Kobe/JP*

Radiological response assessment in the era of bevacizumab: RANO or volumetry? A report from the BELOB trial; *Renske Gahrmann, Rotterdam/NL*

Diagnostic performance of static 18F-fluoroethyl-L-tyrosine positron emission tomography parameters to differentiate recurrent brain tumours from non-neoplastic treatment-related changes: a meta-analysis; *Barbara Muoio, Bellinzona & Lugano/CH*

Long term follow up of radionecrotic brain metastases assessed by serial F-DOPA PET/CT scans; *Francesco Cicone, Rome/IT*

Magnetic resonance spectroscopy for in vivo detection of 2-hydroxyglutarate in lower-grade gliomas; *Elena Anghileri, Milan/IT*

Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response; *Philipp Kickingereder, Heidelberg/DE*

CXCL13 in cerebrospinal fluid (CSF) as a biomarker for primary central nervous system cell lymphoma (PCNSL); *Takashi Sasayama, Kobe/JP*

Improving the intra-operative diagnosis of high-grade glioma using a fluorescence biomarker - A Progress Report of The GALA-BIDD Study; *Colin Watts, Cambridge/UK*

**Oral Session – Glioma Clinical**  
Room: Arnold Schönberg  
**Chairs:** Zvi Ram, Tel Aviv/ISR; Ahmed Idbaih, Paris/FR

Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101; *Wolfgang Wick, Heidelberg/DE*

Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101); *Martin Taphoorn, Leiden/NL*
Stability of actionable mutations in primary and recurrent glioblastomas; Kaspar Draaisma, Rotterdam/NL

Not all 1p/19q non-codeleted oligodendrogial-like tumors are astrocytic; Aden Chan, Shatin/HK

Supratotal resection in low grade gliomas (LGGs): feasibility and clinical impact; Marco Rossi, Milano/IT

Initial treatment strategy for presumed low-grade glioma: a preoperative perspective; Maarten Wijnenga, Rotterdam/NL

First results of the randomized phase II TAVREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma; Ahmed Idbaih, Paris/FR

Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG); Alicia Zukas, Charlottesville/US

**Oral Session - Pediatric Brain Tumors**

**Room:** Alban Berg

**Chairs:** Nada Jabado, Montreal/CAN; Stefan Pfister, Heidelberg/DE

Molecular characterization of astroblastoma; David Capper, Heidelberg/DE

Medulloblastoma recurrence: Improved survival with a metronomic and targeted antiangiogenesis therapy - experience in 18 patients; Irene Slavc, Vienna/AT

Radiosurgery for vascular and tumoral brain lesions in children; Daniel Devriendt, Brussels/BE

Molecular classification of meningiomas across all histological subtypes and grades; Felix Sahm, Heidelberg/DE

The prognostic usability of Ga68-DOTA-TATE PET-CT in irradiated meningioma; Maciej Pelak, Gliwice/PL

CEVOREM Trial : Combination of EVERolimus and Octreotide in RESistant MeningiomasPresentation and Preliminary results; Thomas Graillon, Marseille/FR

Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies: results from the lasON trial; Giulia Berzero, Paris/FR

Family caregivers’ level of mastery predicts survival of glioblastoma patients; Florien Boele, Pittsburgh/US

13:00 – 14:00  **Lunch Break**

14:00 – 15:00 **Plenary Session – Neuro-Oncology at the limits: Neurodevelopmental view on glioma**

**Room:** Gustav Mahler

**Chairs:** Haikun Liu, Heidelberg/DE; Beatrice Melin, Umea/SE

Brain tumor networks; Peter Friedl, Nijmegen/NL

Brain tumor networks; the clinical perspective; Frank Winkler, Heidelberg/DE

Brain-glioma interface; Christopher Mount, Stanford/US
Plenary Session - Germ cell tumors
Room: Arnold Schönberg
Chairs: Ryo Noshikawa, Saitama-Ken/JP; Geoff Pilkington, Portsmouth/UK
Diagnostics; Torsten Pietsch, Bonn/DE
Radiotherapy; Rolf-Dieter Kortmann, Leipzig/DE
Medical treatment; Masao Matsutani, Saitama-Ken/JP
Special focus on children; Lea Guerrini-Rousseau, Villejuif/FR

Plenary Session - Clinical application of brain tumor genetics and epigenetics
Room: Alban Berg
Chairs: Andreas von Deimling, Heidelberg/DE; Antje Wick, Heidelberg/DE
Low-grade gliomas; Sevin Turcan, New York/US
Glioblastoma; Tracy Batchelor, Boston/US
Practical daily application in neurooncology; David Jones, Heidelberg/DE
Metastasis; Manuel Valiente, Madrid/ES

15:00 – 15:45 Keynote lecture ASNO
Room: Gustav Mahler
Chairs: Michael Weller, Zurich/CH
The cellular origin of CNS germ cell tumors; Koichi Ichimura, Tokyo/JP

15:45 – 16:45 Poster viewing

16:45 – 18:15 Hot Topics
Room: Gustav Mahler
WHO Classification; Johan M. Kros, Rotterdam/NL
Radical resection; Hugues Duffau, Montpellier/FR
Biomarkers – to test or not to test, this is the question; Martin van den Bent, Rotterdam/NL
Radiogenomics; Martha Nowosielski, Innsbruck/AT
Second radiotherapy; Stephanie Combs, Munich/DE

Sunday, October 16

08:00 – 09:30 EANO/SNO/ASNO Session: Precision Neuro-Oncology – Glioma/Metastasis
Room: Gustav Mahler
Chairs: Koichi Ichimura, Tokyo/JP; Uwe Schlegel, Bochum/DE
A scientists view; Pim French, Rotterdam/NL
The surgical perspective, Lorenzo Bello, Milan/IT
Radiooncology; Anthony Chalmers, Glasgow/UK
Immunotherapy; David Reardon, Boston/US
Targeted treatments; Wolfgang Wick, Heidelberg/DE
Trial development; Patrick Wen, Boston/US
09:30 – 10:15  **EANO General Assembly**  
*Room: Gustav Mahler*

10:15 – 10:30  **Coffee Break**

10:30 – 11:00  **EORTC Brain Tumor Group: Trial Update**  
*Room: Gustav Mahler*  
*Michael Weller, Zurich/CH*

11:00 – 12:30  **Oral Session – Non-Glioma**  
*Room: Gustav Mahler*  
**Chairs:** Anna Berghoff, Vienna/AT; Emilie Le Rhu, Lille/FR

- Identification and characterization of brain metastasis initiating cells; *Anna Berghoff, Innsbruck/AT*
- A Phase II Study of ANG1005, a novel BBB/BCB Penetrant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer; *Priya Kumthekar, Chicago/US*
- Impact of platelets and coagulation factors on the early steps of the brain metastatic cascade; *Manuel Feinauer, Heidelberg/DE*
- Outcome of patients presenting with brain metastasis as first manifestation of cancer; *Lisa Füreder, Vienna/AT*
- Post-radiation cognitive impairment and hippocampal neuronal depletion measured by in-vivo metabolic MR spectroscopy: Final results of prospective investigational study; *Tomas Kazda, Brno/CZ*
- Management patterns and outcome of patients with primary CNS lymphoma (PCNSL) in France during 2011-2016. A LOC network study; *Caroline Houillier, Paris/FR*
- Feasibility and toxicity of concomitant radiochemotherapy with vincristine in adult patients with medulloblastoma - results from the NOA-07 trial; *Clemens Seidel, Leipzig/DE*

12:30 – 13:15  **Keynote lecture SNO**  
*Room: Gustav Mahler*  
**Chairs:** Wolfgang Wick, Heidelberg/DE

- Uncovering single-cell regulatory programs in human gliomas  
  *Mario Suvà, Boston/US*

13:15 - 13:45  **Poster Awards & Closing remarks**  
*Room: Gustav Mahler*